SMARCA2 and ovarian small cell carcinoma: Recent studies have confirmed that tazemetostat, a selective EZH2 inhibitor, induces effective anti-proliferative and anti-tumor effects in cell lines and xenografts of small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT), which are deficient in both SMARCA2 and SMARCA4 (22).